Showing 1,141 - 1,160 results of 24,497 for search '(( significance ((level decrease) OR (greater disease)) ) OR ( significant decrease decrease ))', query time: 0.56s Refine Results
  1. 1141
  2. 1142

    S1 Data - by Jan Willem Koten (17743224)

    Published 2024
    Subjects:
  3. 1143
  4. 1144
  5. 1145
  6. 1146
  7. 1147
  8. 1148

    Top 10 significant functional annotations of down-regulated DEGs. by Meitner Cadena (22216261)

    Published 2025
    “…Functional annotations are ordered by decreasing significance, with color indicating significance level based on the legend’s color scale, the ratio of genes on the horizontal axis, and DEG count represented by circle size.…”
  9. 1149
  10. 1150
  11. 1151

    Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

    Published 2025
    “…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
  12. 1152

    Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

    Published 2025
    “…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
  13. 1153

    Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

    Published 2025
    “…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
  14. 1154
  15. 1155
  16. 1156
  17. 1157
  18. 1158
  19. 1159
  20. 1160